Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Biotechnology industry for Wednesday, February 05, 2025. Let’s ...

H.C. Wainwright maintained a Buy rating on Vanda Pharmaceuticals (NASDAQ:VNDA) with a price target of $18.00, representing significant upside potential from the current price of $4.31. According to ...

Vanda Pharmaceuticals and AnaptysBio announced an exclusive, global license agreement for the development and commercialization of imsidolimab.

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

Following the agreement, Vanda is preparing BLA and MAA applications for the US and EU, with a focus on commercialization. Imsidolimab, a fully humanized IgG4 antibody, is expected to provide ...

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a ...

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.0, a ...

(Reuters) - Retail investors bought a record amount of Nvidia stock on Monday after concerns over a low-cost artificial ...

Research analysts at StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on ...